Stock A229000 GENCURIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gencurix Inc.

Equities

A229000

KR7229000005

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-19 EDT 		5-day change 1st Jan Change
3,075 KRW -2.84% Intraday chart for Gencurix Inc. -2.84% -50.56%
04-15 J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion. CI
04-03 J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3.2 billion. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 88,980 105,582 117,396 46,147 84,355
Enterprise Value (EV) 1 89,506 107,701 117,767 68,696 89,988
P/E ratio -9.71 x 3.06 x -3.36 x -1.86 x -3.82 x
Yield - - - - -
Capitalization / Revenue 651 x 67.2 x 38.5 x 18 x 32.4 x
EV / Revenue 655 x 68.5 x 38.7 x 26.8 x 34.6 x
EV / EBITDA -15.7 x -11.8 x -9.56 x -6.48 x -8.19 x
EV / FCF - -9,415,578 x -22,129,822 x -3,481,451 x -12,472,392 x
FCF Yield - -0% -0% -0% -0%
Price to Book 573 x 1.98 x 3.81 x 7.31 x 6.13 x
Nbr of stocks (in thousands) 5,393 6,399 6,558 6,669 13,562
Reference price 2 16,500 16,500 17,900 6,920 6,220
Announcement Date 3/18/21 3/18/21 3/23/22 3/23/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 136.6 1,572 3,047 2,559 2,600
EBITDA 1 -5,691 -9,153 -12,313 -10,595 -10,985
EBIT 1 -6,560 -9,267 -12,745 -11,510 -12,376
Operating Margin -4,801.54% -589.48% -418.29% -449.69% -475.93%
Earnings before Tax (EBT) 1 -9,162 32,966 -35,150 -25,452 -20,295
Net income 1 -9,162 33,108 -34,670 -24,597 -19,260
Net margin -6,706.46% 2,106.14% -1,137.86% -961.01% -740.68%
EPS 2 -1,699 5,399 -5,324 -3,721 -1,629
Free Cash Flow - -11,439 -5,322 -19,732 -7,215
FCF margin - -727.65% -174.65% -770.94% -277.47%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/18/21 3/18/21 3/23/22 3/23/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 526 2,119 371 22,549 5,633
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) -0.0925 x -0.2315 x -0.0301 x -2.128 x -0.5128 x
Free Cash Flow - -11,439 -5,322 -19,732 -7,215
ROE (net income / shareholders' equity) - 122% -82.7% -139% -228%
ROA (Net income/ Total Assets) - -17.5% -13.4% -15.5% -21.9%
Assets 1 - -189,692 259,545 158,187 88,074
Book Value Per Share 2 28.80 8,342 4,694 947.0 1,014
Cash Flow per Share 2 104.0 879.0 1,824 878.0 216.0
Capex 1 815 1,124 1,076 13,046 2,056
Capex / Sales 596.44% 71.52% 35.3% 509.71% 79.06%
Announcement Date 3/18/21 3/18/21 3/23/22 3/23/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
GENCURIX INC. Stock Gencurix Inc.
-50.56% 33.78M
BIOMÉRIEUX Stock bioMérieux
-5.27% 12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-3.86% 8.07B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+32.10% 5.52B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-7.35% 4.21B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-55.00% 2.99B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+13.62% 2.73B
VITROLIFE AB Stock Vitrolife AB
-3.65% 2.43B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+31.39% 2.29B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-4.31% 1.89B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. A229000 Stock
  4. Financials Gencurix Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW